公开(公告)号：WO2008033403A3

公开(公告)日：2008-07-24

申请号：PCT/US2007019824

申请日：2007-09-13

Applicant: UNIV COLUMBIA ,  GU HUA ,  JANG IHNKYUNG

Inventor： GU HUA ,  JANG IHNKYUNG

IPC: C07H21/04

CPC classification number: C12N5/0638 ,  A61K2039/5158 ,  A61K2039/57 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/998 ,  C12Q1/25 ,  G01N33/5011 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70539 ,  G01N2333/9015 ,  G01N2500/10

Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.

Abstract translation: 本发明提供了分离的纯化的人细胞群，其包含具有降低的Cbl-b活性的CD8 + T细胞。 本发明提供了这些细胞在诱导或增强受试者中的抗肿瘤免疫应答的方法中的用途。 这些方法包括：（a）提供来自受试者或来自另一来源的包含CD8 + T细胞的细胞群，（b）降低CD8 + T细胞中的Cbl-b活性，（c）将步骤 b）主题。 本发明提供了制备不需要通过共受体刺激的CD8 + T细胞的方法，以便细胞响应经由其T细胞受体的接触而被激活或增殖。 这些方法基于减少Cbl-b的功能。 本发明还提供了鉴定影响Cbl-b表达或活性的试剂的方法。

公开(公告)号：WO2009137801A2

公开(公告)日：2009-11-12

申请号：PCT/US2009043353

申请日：2009-05-08

Applicant: UNIV COLUMBIA ,  GU HUA ,  HAN YOON-CHI ,  PARK CHRISTOPH ,  WEISSMAN IRVING

Inventor： GU HUA ,  HAN YOON-CHI ,  PARK CHRISTOPH ,  WEISSMAN IRVING

IPC: A61K48/00

CPC classification number: C12N15/113 ,  C12N2310/113

Abstract: Provided are compositions and methods for preventing, treating, ameliorating or diagnosing conditions or diseases involving a myeloid cell proliferation disorder. Such compositions and methods target miRNA function myeloproliferative diseases. More particularly, such compositions and methods target miR-29a function in myeloid cell proliferation disorders. Also provided are methods for diagnosing risk or presence of a myeloid cell proliferation disorder in a subject.

Abstract translation: 提供了用于预防，治疗，改善或诊断涉及骨髓细胞增殖病症的病症或疾病的组合物和方法。 这种组合物和方法靶向miRNA功能性骨髓增生性疾病。 更具体地，这样的组合物和方法靶向了miR-29a在骨髓细胞增殖紊乱中的功能。 还提供了用于诊断受试者中骨髓细胞增殖紊乱的风险或存在的方法。